Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02097225 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

22

Enrollment

NIH

Sponsor class

Stopped Drug supply issues

Conditions

BRAF V600E Mutation Present
BRAF V600K Mutation Present
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Unresectable Solid Neoplasm

Interventions

DRUG: Dabrafenib
OTHER: Laboratory Biomarker Analysis
DRUG: Onalespib
OTHER: Pharmacological Study
DRUG: Trametinib

Sponsor

National Cancer Institute (NCI)